A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

2025-524594-16-00 Protocol PH-ACP3GA-03/25 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 12 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol PH-ACP3GA-03/25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 20
Countries 1
Sites 2

Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

Key facts

Sponsor
Philogen S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
12 May 2026 → ongoing
Decision date (initial)
2026-04-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Philogen S.p.A.

Sponsor organisation
Philogen S.p.A.
Address
Piazza La Lizza 7
City
Siena
Postcode
53100
Country
Italy

Scientific contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Public contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 20 2
Rest of world 0

Investigational sites

Italy

2 sites · Ongoing, recruiting
Ospedale San Raffaele S.r.l.
Nuclear Medicine, Via Olgettina 60, 20132, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
SC Nuclear Medicine, Piazza Oms 1, 24127, Bergamo

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2026-05-12 2026-05-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-22 Italy Acceptable
2026-03-27
2026-04-22